Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04754802 · ClinicalTrials.gov registry record · Phase 3
PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge
A Phase 3 study, sponsored by VistaGen Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 224
- Enrollment target
NCT04754802 is a Phase 3 study that has completed, run by VistaGen Therapeutics. The registered enrollment target is 224 participants.
The verdict
NCT04754802, a Phase 3 study, has completed, sponsored by VistaGen Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 224 participants
- Enrollment target
Study Summary
This Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute administration of 3.2 µg of PH94B to relieve symptoms of anxiety in adult subjects with social anxiety disorder (SAD) during an induced public speaking challenge. Subject participation in the Study will last a total of 3 to 7 weeks, depending on the duration of the screening period and intervals between visits. Upon signing an informed consent, all subjects will complete Visit 1 (Screening) and enter a screening period lasting between 3 and 35 days. If subjects meet all eligibility criteria at the end of the screening period, subjects will return for Visit 2 and self-administer the nasal spray and then participate in a 5 minute public speaking challenge. During the public speaking challenge, the subject will be asked for their anxiety score, which will be recorded by a trained observer. At Visit 3, the subjects will undergo the same public speaking procedure once again as they did in Visit 2. One week after the completion of the Visit 3 public speaking challenge, the subject will come back for Visit 4 (Follow-up) that will involve a repeat of the safety and psychiatric assessments conducted at Screening.
Interventions
- DRUG Placebo Nasal Spray
- DRUG PH94B Nasal Spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2021-05-24 |
| Est. Completion | 2022-06-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04754802
The ClinicalTrials.gov registry entry for NCT04754802 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VistaGen Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Nasal Spray is the first listed.
NCT04754802 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04754802 about?
NCT04754802 is a clinical study titled "PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge". This Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute administration of 3.2 µg of PH94B to relieve symptoms of anxiety in adult subjects with social anxiety disorder (SAD) during an induced public speaking challenge. Subject participation in the Stu...
What is the current status of trial NCT04754802?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 224 participants. The study started on 2021-05-24. Estimated completion is 2022-06-22.
What interventions are being tested in trial NCT04754802?
The interventions under investigation include: Placebo Nasal Spray (DRUG), PH94B Nasal Spray (DRUG).
Who is sponsoring clinical trial NCT04754802?
This trial is sponsored by VistaGen Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.